Novartis AG ADR (NVS)vsTscan Therapeutics Inc (TCRX)
NVS
Novartis AG ADR
$160.79
+0.45%
HEALTHCARE · Cap: $303.67B
TCRX
Tscan Therapeutics Inc
$0.18
+2.69%
HEALTHCARE · Cap: $12.86M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 806594% more annual revenue ($57.36B vs $7.11M). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
TCRX
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$160.79
$65.23 premium
Intrinsic value data unavailable for TCRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : TCRX
The primary concerns for TCRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
TCRX carries more volatility with a beta of 1.14 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 35/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor (TCR) discovery platform. The firm is dedicated to developing a diverse pipeline of TCR-based therapeutics targeting specific cancer antigens, with the objective of enhancing patient outcomes across various malignancies. With a strong intellectual property portfolio and a strategic emphasis on T cell-based immunotherapies, Tscan is well-positioned to meet significant unmet medical needs in the oncology sector, standing out in a competitive and rapidly evolving market.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?